Table 1.

Patients’ characteristics and immunohistochemistry staining.

	No. of cases	IHC-pAKT			IHC-CD44
		Negative/weak	Strong	p	Negative/weak	Strong	p
Sex
Male	153	109 (71%)	44 (29%)	0.5445	85 (56%)	67 (44%)	0.3504
Female	30	23 (77%)	7 (23%)		15 (47%)	17 (53%)
Age
≤60	49	36 (73%)	13 (27%)	0.8071	22 (45%)	27 (55%)	0.121
>60	134	96 (72%)	38 (28%)		78 (58%)	57 (42%)
Degree of diffr.
I + II	138	99 (72%)	39 (28%)	0.8359	69 (50%)	70 (50%)	0.0315
III	45	33 (73%)	12 (27%)		30 (68%)	14 (32%)
LN metastasis
No	108	72 (67%)	36 (33%)	0.0479	61 (60%)	40 (40%)	0.0711
Yes	75	60 (80%)	15 (20%)		33 (46%)	38 (54%)
Clinical stage
I + II	132	94 (76%)	29 (24%)	0.0637	69 (53%)	62 (47%)	0.5388
III + IV	51	38 (63%)	22 (37%)		30 (58%)	22 (42%)
Resection status
R0	168	119 (71%)	49 (29%)	0.19	89 (54%)	77 (46%)	0.6814
R1 + 2	15	13 (87%)	2 (13%)		10 (59%)	7 (41%)
IHC-pAKT1
Negative/weak	132				78	48	0.0012
Strong	51				17	32
IHC-CD44
Negative/weak	100	78	17	0.0012
Strong	84	48	32
FISH-FGFR1
Negative	105	68	37	0.1564	46	57	0.2559
Positive	32	25	7		19	15
IHC-FGFR1
Negative/weak	109	81	28	0.1142	61	71	<0.0001
Strong	50	31	19		25	3

Bold values represent significant p-value  <  0.05.

p values were calculated with the chi-squared test; significant values are indicated in bold type.

­diffr. differentiation, LN lymph node.